首页 > 最新文献

Klinicka Onkologie最新文献

英文 中文
A unique case of a giant ovarian mucinous cystadenoma causing an acute renal failure and compartment syndrome. 一个独特的情况下,巨大的卵巢粘液囊腺瘤引起急性肾功能衰竭和室室综合征。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko202365
V Bartoš, M Krištofík

Background: Mucinous cystadenoma of the ovary is a common gynecologic tumor that usually has a very favorable prognosis. However, if it is not early detected and removed, it can grow to a large size and may cause serious health complications.

Case: A 65-year-old woman was transported to the hospital by the emergency medical service due to overall weakness, markedly enlarged abdomen reminiscent of ascites, breathing difficulties, and swollen legs with eczematous ulcers. Laboratory parameters showed an acute renal insufficiency. Imaging scans revealed a giant solid cystic tumor mass filling the whole abdominopelvic cavity, which caused a compartment syndrome of the lower limbs. After relieving puncture and drainage of 6 L of fluid from the cyst, laparotomy had been performed. Grossly, the entire abdominal cavity was filled with a huge cystic tumor originating from the left ovary. During its surgical preparation, a total of 17 L of fluid was evacuated from it. Then, adnexectomy was made. A bio-psy sample consisted of an irregular, artificially teared multicystic tumor about 60 cm in the largest dimension. Histology confirmed a benign mucinous cystadenoma. After tumor removal, the patient's health condition and laboratory parameters improved.

Conclusion: We described a unique case of an extremely huge ovarian mucinous cystadenoma that led to a life-threating event of the patient. We tried to point out that even a "common" benign tumor may lead to clinically malignant consequences and its management requires a multidisciplinary approach.

背景:卵巢粘液囊腺瘤是一种常见的妇科肿瘤,通常预后良好。然而,如果不及早发现并切除,它可能会长得很大,并可能导致严重的健康并发症。病例:一名65岁女性,因全身虚弱、腹部明显增大,令人想起腹水、呼吸困难和腿部肿胀伴湿疹性溃疡被紧急医疗服务送往医院。实验室参数显示急性肾功能不全。成像扫描显示一个巨大的实性囊性肿瘤肿块充满整个腹腔,引起下肢隔室综合征。在解除穿刺并从囊肿中抽出6升液体后,进行剖腹手术。肉眼可见,整个腹腔充满了源自左侧卵巢的巨大囊性肿瘤。在手术准备过程中,共排出17 L液体。然后行附件切除术。活检样本包括一个不规则的,人工撕裂的多囊肿瘤,最大尺寸约60厘米。组织学证实为良性粘液囊腺瘤。肿瘤切除后,患者的健康状况和实验室参数得到改善。结论:我们描述了一个独特的情况下,一个巨大的卵巢粘液囊腺瘤,导致患者的生命危险事件。我们试图指出,即使是一个“常见的”良性肿瘤也可能导致临床恶性后果,其治疗需要多学科的方法。
{"title":"A unique case of a giant ovarian mucinous cystadenoma causing an acute renal failure and compartment syndrome.","authors":"V Bartoš,&nbsp;M Krištofík","doi":"10.48095/ccko202365","DOIUrl":"https://doi.org/10.48095/ccko202365","url":null,"abstract":"<p><strong>Background: </strong>Mucinous cystadenoma of the ovary is a common gynecologic tumor that usually has a very favorable prognosis. However, if it is not early detected and removed, it can grow to a large size and may cause serious health complications.</p><p><strong>Case: </strong>A 65-year-old woman was transported to the hospital by the emergency medical service due to overall weakness, markedly enlarged abdomen reminiscent of ascites, breathing difficulties, and swollen legs with eczematous ulcers. Laboratory parameters showed an acute renal insufficiency. Imaging scans revealed a giant solid cystic tumor mass filling the whole abdominopelvic cavity, which caused a compartment syndrome of the lower limbs. After relieving puncture and drainage of 6 L of fluid from the cyst, laparotomy had been performed. Grossly, the entire abdominal cavity was filled with a huge cystic tumor originating from the left ovary. During its surgical preparation, a total of 17 L of fluid was evacuated from it. Then, adnexectomy was made. A bio-psy sample consisted of an irregular, artificially teared multicystic tumor about 60 cm in the largest dimension. Histology confirmed a benign mucinous cystadenoma. After tumor removal, the patient's health condition and laboratory parameters improved.</p><p><strong>Conclusion: </strong>We described a unique case of an extremely huge ovarian mucinous cystadenoma that led to a life-threating event of the patient. We tried to point out that even a \"common\" benign tumor may lead to clinically malignant consequences and its management requires a multidisciplinary approach.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Image guided adaptive brachytherapy of cervical cancer - practical recommendations. 影像引导下宫颈癌适应性近距离放射治疗的实用建议。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko202396
R Vojtíšek

Brachytherapy (BT) is an integral part of radical radiotherapy (RT) or radiochemotherapy (RCT) in patients who are not suitable candidates for surgery. These are usually patients with locally advanced cervical cancer. The goal of all BT planning eff orts has been, still is, and certainly will continue to be, to defi ne the anatomical boundaries of the tumor and the relationship of the tumor to organs at risk (OARs) as best as possible, using available modern imaging techniques. Image guided adaptive brachytherapy (IGABT) is currently the most advanced method of uterovaginal BT. Adaptive planning allows dose escalation from BT to newly defi ned target volumes, according to the risk of recurrence, which is mainly determined by the level of tumor burden. This dose adaptation based on the response to external RCT is a major change in practice compared to conventional BT planning based on dose prescription to point A. The main advantage of the IGABT concept is that it allows the assessment of individual dose distributions in target volumes and OARs, which in turn leads to improved dose coverage of target volumes while decreasing the volume irradiated by the prescribed dose compared to conventional 2D planning. Purpose: In this review article, I provide a comprehensive up-to-date perspective on this issue, particularly in terms of practical recommendations regarding the defi nition of target volumes, the use of diff erent types of uterovaginal applicators, intraoperative complications, and potential manifestations of late gastrointestinal, genitourinary, and vaginal toxicity.

对于不适合手术的患者,近距离放疗(BT)是根治性放疗(RT)或放化疗(RCT)的重要组成部分。这些患者通常是局部晚期宫颈癌患者。所有BT计划工作的目标一直是,现在仍然是,并且肯定会继续是,利用现有的现代成像技术,尽可能地确定肿瘤的解剖边界和肿瘤与危险器官(OARs)的关系。图像引导适应性近距离放射治疗(IGABT)是目前最先进的子宫阴道BT治疗方法,适应性规划允许根据复发风险(主要由肿瘤负荷水平决定)从BT剂量递增到新定义的目标体积。与基于a点剂量处方的传统BT计划相比,这种基于外部RCT反应的剂量调整在实践中是一个重大变化。IGABT概念的主要优势在于,它允许评估靶体积和桨叶中的个体剂量分布,这反过来又导致靶体积的剂量覆盖得到改善,同时与传统的二维计划相比,规定剂量照射的体积减小。目的:在这篇综述文章中,我就这一问题提供了一个全面的最新观点,特别是关于靶体积的定义、不同类型子宫阴道涂布器的使用、术中并发症以及晚期胃肠道、泌尿生殖系统和阴道毒性的潜在表现方面的实用建议。
{"title":"Image guided adaptive brachytherapy of cervical cancer - practical recommendations.","authors":"R Vojtíšek","doi":"10.48095/ccko202396","DOIUrl":"https://doi.org/10.48095/ccko202396","url":null,"abstract":"<p><p>Brachytherapy (BT) is an integral part of radical radiotherapy (RT) or radiochemotherapy (RCT) in patients who are not suitable candidates for surgery. These are usually patients with locally advanced cervical cancer. The goal of all BT planning eff orts has been, still is, and certainly will continue to be, to defi ne the anatomical boundaries of the tumor and the relationship of the tumor to organs at risk (OARs) as best as possible, using available modern imaging techniques. Image guided adaptive brachytherapy (IGABT) is currently the most advanced method of uterovaginal BT. Adaptive planning allows dose escalation from BT to newly defi ned target volumes, according to the risk of recurrence, which is mainly determined by the level of tumor burden. This dose adaptation based on the response to external RCT is a major change in practice compared to conventional BT planning based on dose prescription to point A. The main advantage of the IGABT concept is that it allows the assessment of individual dose distributions in target volumes and OARs, which in turn leads to improved dose coverage of target volumes while decreasing the volume irradiated by the prescribed dose compared to conventional 2D planning. Purpose: In this review article, I provide a comprehensive up-to-date perspective on this issue, particularly in terms of practical recommendations regarding the defi nition of target volumes, the use of diff erent types of uterovaginal applicators, intraoperative complications, and potential manifestations of late gastrointestinal, genitourinary, and vaginal toxicity.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9419857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis. 摘要罕见的尿路上皮癌转移至胆囊壁,表现为急性胆囊炎。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023401
A Berková, Z Chovanec, I Krejčová, J Katolická, Z Bednařík, V Červeňák, P Vlček, I Penka

Background: Metastasis to the gallbladder is very rare. This case report highlights a rare cause of acute cholecystitis, which should be considered by the surgeon and other treating physicians in the differential diagnosis of patients with urothelial carcinoma.

Case: We report the case of a 73 year-old man with follow-up oncology care. He was diagnosed with infiltrating urothelial carcinoma in 2019, received neoadjuvant chemotherapy, and subsequently underwent radical cystectomy with ureteroileostomy in April 2020. Histology confirmed complete regression of bladder cancer, the lymphonodes were also free of tumour infiltration. In July 2021, the patient was examined for intermittent abdominal pain, predominantly of the right upper quadrant. On clinical examination, the gallbladder hydrops was palpable and a positive Murphy's sign was present. Due to the signs of acute cholecystitis, the patient was indicated for acute cholecystectomy. Gallbladder histology revealed metastatic involvement of the gallbladder wall by urothelial carcinoma.

Conclusion: If patients with bladder cancer present with intermittent right subcostal pain or signs of acute cholecystitis and diagnostic imaging shows a thickened gallbladder wall, clinicians and radiologists should consider the possibility of metastatic origin of lesion.

背景:胆囊转移是非常罕见的。本病例报告强调了急性胆囊炎的一种罕见原因,外科医生和其他治疗医生在鉴别诊断尿路上皮癌患者时应考虑这一点。病例:我们报告一位73岁男性的病例,接受后续肿瘤治疗。他于2019年被诊断为浸润性尿路上皮癌,接受了新辅助化疗,随后于2020年4月接受了输尿管回肠造口术根治性膀胱切除术。组织学证实癌症完全消退,淋巴结也没有肿瘤浸润。2021年7月,患者接受了间歇性腹痛检查,主要是右上象限。在临床检查中,胆囊积水是可触摸的,并出现阳性墨菲征。由于急性胆囊炎的症状,该患者被要求进行急性胆囊切除术。胆囊组织学显示尿路上皮癌转移到胆囊壁。结论:如果癌症患者出现间歇性右肋下疼痛或急性胆囊炎体征,且诊断性影像学显示胆囊壁增厚,临床医生和放射科医生应考虑病灶转移来源的可能性。
{"title":"A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis.","authors":"A Berková,&nbsp;Z Chovanec,&nbsp;I Krejčová,&nbsp;J Katolická,&nbsp;Z Bednařík,&nbsp;V Červeňák,&nbsp;P Vlček,&nbsp;I Penka","doi":"10.48095/ccko2023401","DOIUrl":"10.48095/ccko2023401","url":null,"abstract":"<p><strong>Background: </strong>Metastasis to the gallbladder is very rare. This case report highlights a rare cause of acute cholecystitis, which should be considered by the surgeon and other treating physicians in the differential diagnosis of patients with urothelial carcinoma.</p><p><strong>Case: </strong>We report the case of a 73 year-old man with follow-up oncology care. He was diagnosed with infiltrating urothelial carcinoma in 2019, received neoadjuvant chemotherapy, and subsequently underwent radical cystectomy with ureteroileostomy in April 2020. Histology confirmed complete regression of bladder cancer, the lymphonodes were also free of tumour infiltration. In July 2021, the patient was examined for intermittent abdominal pain, predominantly of the right upper quadrant. On clinical examination, the gallbladder hydrops was palpable and a positive Murphy's sign was present. Due to the signs of acute cholecystitis, the patient was indicated for acute cholecystectomy. Gallbladder histology revealed metastatic involvement of the gallbladder wall by urothelial carcinoma.</p><p><strong>Conclusion: </strong>If patients with bladder cancer present with intermittent right subcostal pain or signs of acute cholecystitis and diagnostic imaging shows a thickened gallbladder wall, clinicians and radiologists should consider the possibility of metastatic origin of lesion.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic body radiation therapy in the treatment of early-stage non-small cell lung cancer. 立体定向体放射治疗早期非小细胞肺癌。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023370
K Resová, T Paračková, J Cvek

Background: Stereotactic body radiation therapy (SBRT) is now a standard treatment option for patients with early-stage non-small cell lung cancer (ES-NSCLC) who are unfit for surgery or refuse to undergo an operation. SBRT is a method of external beam radiotherapy that accurately delivers a high dose of irradiation in one or few treatment fractions. Intensive regimens of biologically effective dose ≥ 100 Gy are associated with good local control and overall survival, higher than in conventionally fractionated radiotherapy. There are still controversial areas in the SBRT indication where data are limited - indications for elderly and comorbid patients, indications for treatment without histological verification, treatment of central/ultracentral lesions, indications for tumors larger than 5 cm, indications for operable patients. The optimal follow-up practice of these patients also remains unclear, including the frequency of imaging, the use of PET-CT, and requirements for biopsy. CT changes after SBRT differ from those following conventional radiotherapy and it is difficult to distinguish them from tumor recurrence. Due to the high local control achieved with lung SBRT, data on the treatment of local failure are insufficient.

Purpose: The aim of the publication is to demonstrate the current information and the importance of SBRT for patients with ES-NSCLC.

背景:立体定向身体放射治疗(SBRT)目前是不适合手术或拒绝手术的早期癌症(ES-NSCLC)患者的标准治疗选择。SBRT是一种外束放射治疗方法,可以在一个或几个治疗部分中准确地提供高剂量的照射。生物学有效剂量≥100 Gy的强化方案与良好的局部控制和总生存率相关,高于常规分割放疗。SBRT适应症仍有争议,数据有限——老年和合并症患者的适应症、未经组织学验证的治疗适应症、中心/超中心病变的治疗、大于5的肿瘤的适应症 cm,可手术患者的适应症。这些患者的最佳随访实践也不清楚,包括成像频率、PET-CT的使用和活检要求。SBRT后的CT变化与常规放疗后的不同,很难将其与肿瘤复发区分开来。由于肺SBRT实现了高度的局部控制,关于局部衰竭治疗的数据不足。目的:该出版物的目的是证明SBRT对ES-NSCLC患者的当前信息和重要性。
{"title":"Stereotactic body radiation therapy in the treatment of early-stage non-small cell lung cancer.","authors":"K Resová,&nbsp;T Paračková,&nbsp;J Cvek","doi":"10.48095/ccko2023370","DOIUrl":"10.48095/ccko2023370","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic body radiation therapy (SBRT) is now a standard treatment option for patients with early-stage non-small cell lung cancer (ES-NSCLC) who are unfit for surgery or refuse to undergo an operation. SBRT is a method of external beam radiotherapy that accurately delivers a high dose of irradiation in one or few treatment fractions. Intensive regimens of biologically effective dose ≥ 100 Gy are associated with good local control and overall survival, higher than in conventionally fractionated radiotherapy. There are still controversial areas in the SBRT indication where data are limited - indications for elderly and comorbid patients, indications for treatment without histological verification, treatment of central/ultracentral lesions, indications for tumors larger than 5 cm, indications for operable patients. The optimal follow-up practice of these patients also remains unclear, including the frequency of imaging, the use of PET-CT, and requirements for biopsy. CT changes after SBRT differ from those following conventional radiotherapy and it is difficult to distinguish them from tumor recurrence. Due to the high local control achieved with lung SBRT, data on the treatment of local failure are insufficient.</p><p><strong>Purpose: </strong>The aim of the publication is to demonstrate the current information and the importance of SBRT for patients with ES-NSCLC.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analyzing the impact of close margins and extra-resection margins on failure rates in postoperative oral cavity cancers. 分析近边缘和切除外边缘对口腔癌术后失败率的影响。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023467
V Shivhare, S Rath, H Rathod, N K Dash, A Parikh, U Suryanarayan Kunikullaya

Background: Postoperative oral cancers with close margins belong to medium- to high-risk category for local failure. During re-surgery for close margins, there is sufficient doubt as to whether the re-excised tissue is from the same region as the close margin. Therefore, we planned a retrospective review of these cases of close margins that were re-excised with extra-resection margins (ERMs).

Material and methods: Details of 2011 oral cavity patients resected at our hospital were retrieved. Cases with close margins were segregated and the status of ERMs was noted. The postoperative histopathological details, radiotherapy details, and failure patterns in all these cases were documented. The primary objective of the study was to assess the overall survival (OS) and disease-free survival (DFS) in cases with ERMs. The secondary objective was to assess the local and regional control rates and variation with the number and status of close and ERMs. OS, DFS, and local failure rates were defined from the date of registration. Statistical analysis was performed with the SPSS statistical software package. All survival analyses were performed using the Kaplan-Meier method. Log-rank test was used to test the statistical significance. A P-value of 0.05 was considered statistically significant.

Results: Sixty-four cases with a median age of 47 years (range: 29-76) were considered for the final analysis. The median follow-up was 40 months (range: 9.5-56.5). The 2-year OS and DFS rates were 91.5% and 88.5%, respectively. The crude local and regional failure rates were 10.9% and 3.1%, respectively. The 3-year locoregional control rate was 90.2%. The 2-year locoregional control rate for one close margin was significantly better as compared to more than one close margin (P = 0.049). No difference in survival and failure rates was found between the number of ERMs resected (one vs. two) and ≤ vs. > 3 mm close margin status. Two patients developed bone metastases.

Conclusion: The survival rates and locoregional control rates did not differ much between the groups that had one or more ERMs. However, the locoregional control rates were better in cases with one close margin as compared to those with more than one close margin. A larger study with longer follow-up is needed to detect statistically significant differences in outcomes and identify the factors that portend poor prognosis in these cases with close margins and ERMs.

背景:手术后边缘较近的口腔癌属于局部失败的中高风险类别。在近边缘再手术过程中,人们对再次切除的组织是否与近边缘来自同一区域有足够的怀疑。因此,我们计划对这些用切口外缘(ERM)再次切除的近缘病例进行回顾性审查:材料: 我们检索了 2011 年在本医院接受切除手术的口腔患者的详细资料。材料:检索了本医院 2011 年口腔癌切除患者的详细资料,对边缘较近的病例进行了分类,并记录了切除边缘的情况。记录所有这些病例的术后组织病理学细节、放疗细节和失败模式。研究的主要目的是评估 ERM 病例的总生存期(OS)和无病生存期(DFS)。次要目标是评估局部和区域的控制率,以及近端和ERM的数量和状态的变化。OS、DFS和局部失败率自登记之日起定义。统计分析使用 SPSS 统计软件包进行。所有生存分析均采用 Kaplan-Meier 法。对数秩检验用于检验统计显著性。P值为0.05即为具有统计学意义:最终分析了 64 例病例,中位年龄为 47 岁(29-76 岁)。中位随访时间为 40 个月(9.5-56.5 个月)。2年的OS和DFS率分别为91.5%和88.5%。粗略的局部和区域失败率分别为10.9%和3.1%。3年局部区域控制率为90.2%。2年的局部区域控制率中,一个近端边缘的控制率明显优于一个以上近端边缘的控制率(P = 0.049)。切除的ERM数量(1个与2个)以及≤与> 3 mm的切缘状态在生存率和失败率方面没有差异。两名患者出现骨转移:结论:切除一个或多个ERM的患者组之间的生存率和局部控制率差别不大。结论:有一个或多个ERM的组别在生存率和局部控制率方面没有太大差异,但有一个闭合边缘的病例的局部控制率优于有一个以上闭合边缘的病例。需要进行更大规模、更长时间的随访研究,以检测结果是否存在统计学意义上的显著差异,并确定哪些因素预示着边缘较近和有 ERM 的病例预后较差。
{"title":"Analyzing the impact of close margins and extra-resection margins on failure rates in postoperative oral cavity cancers.","authors":"V Shivhare, S Rath, H Rathod, N K Dash, A Parikh, U Suryanarayan Kunikullaya","doi":"10.48095/ccko2023467","DOIUrl":"10.48095/ccko2023467","url":null,"abstract":"<p><strong>Background: </strong>Postoperative oral cancers with close margins belong to medium- to high-risk category for local failure. During re-surgery for close margins, there is sufficient doubt as to whether the re-excised tissue is from the same region as the close margin. Therefore, we planned a retrospective review of these cases of close margins that were re-excised with extra-resection margins (ERMs).</p><p><strong>Material and methods: </strong>Details of 2011 oral cavity patients resected at our hospital were retrieved. Cases with close margins were segregated and the status of ERMs was noted. The postoperative histopathological details, radiotherapy details, and failure patterns in all these cases were documented. The primary objective of the study was to assess the overall survival (OS) and disease-free survival (DFS) in cases with ERMs. The secondary objective was to assess the local and regional control rates and variation with the number and status of close and ERMs. OS, DFS, and local failure rates were defined from the date of registration. Statistical analysis was performed with the SPSS statistical software package. All survival analyses were performed using the Kaplan-Meier method. Log-rank test was used to test the statistical significance. A P-value of 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Sixty-four cases with a median age of 47 years (range: 29-76) were considered for the final analysis. The median follow-up was 40 months (range: 9.5-56.5). The 2-year OS and DFS rates were 91.5% and 88.5%, respectively. The crude local and regional failure rates were 10.9% and 3.1%, respectively. The 3-year locoregional control rate was 90.2%. The 2-year locoregional control rate for one close margin was significantly better as compared to more than one close margin (P = 0.049). No difference in survival and failure rates was found between the number of ERMs resected (one vs. two) and ≤ vs. &gt; 3 mm close margin status. Two patients developed bone metastases.</p><p><strong>Conclusion: </strong>The survival rates and locoregional control rates did not differ much between the groups that had one or more ERMs. However, the locoregional control rates were better in cases with one close margin as compared to those with more than one close margin. A larger study with longer follow-up is needed to detect statistically significant differences in outcomes and identify the factors that portend poor prognosis in these cases with close margins and ERMs.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Classification of germline variants identified in cancer predisposition genetic testing - consensus of the CZECANCA consortium. 癌症易感基因检测中发现的种系变异的分类--CZECANCA 联合会的共识。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023431
M Janatová, Š Chvojka, E Macháčková, J Soukupová, P Zemánková, P Nehasil, T Zavoral, L Hrušková, K M Kozáková Janíková, F Lhota, S Tavandzis, P Kleiblová, Z Kleibl, Czecanca Konzorcium

Background: Hereditary cancer syndromes are an important subset of malignant cancers caused by pathogenic variants in one of many known cancer predisposition genes. Diagnosis of cancer predisposition is based on genetic testing using next-generation sequencing. This allows many genes to be analysed at once, increasing the number of variants identified. The correct classification of the variants found is essential for the clinical interpretation of genetic test results.

Purpose: The aim of this study is to summarise the rules for classifying identified variants within individual laboratories and to present the process for creating a common classification. In the Czech Republic, the sharing of identified genetic variants and the development of their consensus classification among national laboratory diagnostic communities is carried out within the Czech Cancer Panel for Clinical Application (CZECANCA) consortium of scientific and diagnostic oncogenetic laboratories. Consensus for variant classification follows a defined protocol. Sharing the results and consensus classification accelerates and refines the release of genetic test results, harmonises results between laboratories and thus contributes to improving the care of individuals at high risk of cancer and their relatives.

背景:遗传性癌症综合征是恶性癌症的一个重要子集,由许多已知癌症易感基因中的一个基因的致病变异引起。癌症易感性的诊断基于使用新一代测序技术进行的基因检测。这样可以同时对许多基因进行分析,从而增加所发现变异的数量。目的:本研究的目的是总结各实验室对已识别变异体进行分类的规则,并介绍创建通用分类的过程。在捷克共和国,国家实验室诊断团体之间共享已确定的基因变异体并制定其共识分类法的工作是在由科学和肿瘤基因诊断实验室组成的捷克癌症临床应用小组(CZECANCA)联盟内进行的。变异分类共识遵循既定的协议。共享结果和共识分类可加快和完善基因检测结果的发布,协调各实验室之间的结果,从而有助于改善对癌症高危人群及其亲属的护理。
{"title":"Classification of germline variants identified in cancer predisposition genetic testing - consensus of the CZECANCA consortium.","authors":"M Janatová, Š Chvojka, E Macháčková, J Soukupová, P Zemánková, P Nehasil, T Zavoral, L Hrušková, K M Kozáková Janíková, F Lhota, S Tavandzis, P Kleiblová, Z Kleibl, Czecanca Konzorcium","doi":"10.48095/ccko2023431","DOIUrl":"10.48095/ccko2023431","url":null,"abstract":"<p><strong>Background: </strong>Hereditary cancer syndromes are an important subset of malignant cancers caused by pathogenic variants in one of many known cancer predisposition genes. Diagnosis of cancer predisposition is based on genetic testing using next-generation sequencing. This allows many genes to be analysed at once, increasing the number of variants identified. The correct classification of the variants found is essential for the clinical interpretation of genetic test results.</p><p><strong>Purpose: </strong>The aim of this study is to summarise the rules for classifying identified variants within individual laboratories and to present the process for creating a common classification. In the Czech Republic, the sharing of identified genetic variants and the development of their consensus classification among national laboratory diagnostic communities is carried out within the Czech Cancer Panel for Clinical Application (CZECANCA) consortium of scientific and diagnostic oncogenetic laboratories. Consensus for variant classification follows a defined protocol. Sharing the results and consensus classification accelerates and refines the release of genetic test results, harmonises results between laboratories and thus contributes to improving the care of individuals at high risk of cancer and their relatives.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extra-cellular exosomes may have the role of a carrier in transferring molecules from the tumor micro-environment to the unaffected cells in breast cancer tumors. 细胞外的外泌体可能起到载体的作用,将肿瘤微环境中的分子转移到乳腺癌肿瘤中未受影响的细胞中。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023462
S A Khani, M Kavousi, F Jamshidian

Background: Breast cancer is recognized as a major clinical challenge in gynecological diseases worldwide. Exosomes are small vesicles derived from multicellular bodies that are secreted by many cells into the extracellular environment and thus participate in intercellular communication through the transfer of genetic information such as encoded and non-encoded RNAs to target cells. Tumor-derived exosomes are thought to be a rich source of microRNAs (miRNAs) that can regulate the function of other cancer cells in the tumor microenvironment. However, the exact mechanisms by which tumor cell-derived exosomes affect their neighboring cells, as well as the biological function of exosomal miRNAs in receptor cells, are not well understood.

Materials and methods: In this study, after overexpression of miR-205 in breast cancer cells (MDA-MB-231 class), cell-derived exosomes were successfully isolated and characterized by electron microscopy and dynamic light scattering.

Results: Determination of miR-205 expression levels in exosomes secreted from engineered cells confirmed the high expression of this miRNA in exosomes. It was also found that treatment of tumor exosomes carrying this miRNA had an apoptotic induction effect and also had a significant effect on reducing the expression of Bcl-2 gene transcript in a time-dependent manner in breast cancer cells (P < 0.001).

Conclusion: Overall, this study suggests that exosomal transfer of tumor suppressor miRNAs to cancer cells could be a suitable platform for nucleic acid transfer to these cells and be highly effective in cancer treatment.

背景:乳腺癌是全球公认的妇科疾病中的一大临床难题。外泌体是源自多细胞体的小囊泡,由许多细胞分泌到细胞外环境中,从而通过向靶细胞传递编码和非编码 RNA 等遗传信息参与细胞间通信。肿瘤外泌体被认为是微RNA(miRNA)的丰富来源,可调节肿瘤微环境中其他癌细胞的功能。然而,肿瘤细胞衍生的外泌体影响其邻近细胞的确切机制以及外泌体miRNA在受体细胞中的生物学功能尚不十分清楚:本研究在乳腺癌细胞(MDA-MB-231 类)中过表达 miR-205 后,成功分离了细胞衍生的外泌体,并通过电子显微镜和动态光散射对其进行了表征:结果:对工程细胞分泌的外泌体中 miR-205 表达水平的测定证实,这种 miRNA 在外泌体中的表达量很高。结果:通过检测工程细胞分泌的外泌体中 miR-205 的表达水平,证实了该 miRNA 在外泌体中的高表达,同时还发现携带该 miRNA 的肿瘤外泌体具有诱导细胞凋亡的作用,并能显著降低乳腺癌细胞中 Bcl-2 基因转录本的表达,其表达量呈时间依赖性(P < 0.001):总之,这项研究表明,将肿瘤抑制miRNA外泌体转移到癌细胞可能是一种合适的核酸转移平台,在癌症治疗中非常有效。
{"title":"Extra-cellular exosomes may have the role of a carrier in transferring molecules from the tumor micro-environment to the unaffected cells in breast cancer tumors.","authors":"S A Khani, M Kavousi, F Jamshidian","doi":"10.48095/ccko2023462","DOIUrl":"10.48095/ccko2023462","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is recognized as a major clinical challenge in gynecological diseases worldwide. Exosomes are small vesicles derived from multicellular bodies that are secreted by many cells into the extracellular environment and thus participate in intercellular communication through the transfer of genetic information such as encoded and non-encoded RNAs to target cells. Tumor-derived exosomes are thought to be a rich source of microRNAs (miRNAs) that can regulate the function of other cancer cells in the tumor microenvironment. However, the exact mechanisms by which tumor cell-derived exosomes affect their neighboring cells, as well as the biological function of exosomal miRNAs in receptor cells, are not well understood.</p><p><strong>Materials and methods: </strong>In this study, after overexpression of miR-205 in breast cancer cells (MDA-MB-231 class), cell-derived exosomes were successfully isolated and characterized by electron microscopy and dynamic light scattering.</p><p><strong>Results: </strong>Determination of miR-205 expression levels in exosomes secreted from engineered cells confirmed the high expression of this miRNA in exosomes. It was also found that treatment of tumor exosomes carrying this miRNA had an apoptotic induction effect and also had a significant effect on reducing the expression of Bcl-2 gene transcript in a time-dependent manner in breast cancer cells (P &lt; 0.001).</p><p><strong>Conclusion: </strong>Overall, this study suggests that exosomal transfer of tumor suppressor miRNAs to cancer cells could be a suitable platform for nucleic acid transfer to these cells and be highly effective in cancer treatment.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating changes in the post-transcriptional pattern of VEGF and CD146 genes carrying miR-573 in breast cancer cells treated with tamoxifen. 研究他莫昔芬治疗的乳腺癌细胞中携带 miR-573 的血管内皮生长因子和 CD146 基因转录后模式的变化。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023447
M Abyar, M Kavousi, F Jamshidian

Background: Recent developments regarding the contribution of microRNAs (miRNAs) to tumor angiogenesis and the oncogenic effects of miRNAs point to their potential role in breast cancer angiogenesis. Tumor-derived exosomes are considered a rich source of miRNAs that can regulate the function of other cells in the tumor microenvironment, including vascular endothelial cells. This study analyzes the effect of tamoxifen chemotherapy on the expression of a key miRNA, miR-573, involved in the angiogenesis of the tumor exosomes and introduces a regulatory link between this miRNA and the CD146 gene associated with the vascular endothelial growth factor (VEGF) messaging pathway.

Materials and methods: MCF-7 breast cancer cells were purchased and cultured in a complete culture medium. These cells were treated with tamoxifen and then their exosomes were extracted from the culture medium. The RNAs of the exosomes were isolated and the expression of miR-573, VEGF, and CD146 genes in the exosomes was investigated using the real-time polymerase chain reaction (PCR) method.

Results: The results of this study showed that tamoxifen treatment increased the expression of miR-573 in exosomes derived from MCF-7 cancer cells. The expression of CD146 and VEGF genes in drug-treated cell exosomes had a downward pattern.

Conclusion: The results of this experiment demonstrated that the treatment of breast cancer cells with tamoxifen reduces the expression of VEGF and CD146 by increasing miR-573. Thus, angiogenesis is reduced and, therefore, its anti-tumor effects are applied.

背景:有关微RNA(miRNA)对肿瘤血管生成的贡献以及miRNA致癌作用的最新进展表明,miRNA在乳腺癌血管生成中具有潜在作用。肿瘤衍生的外泌体被认为是miRNAs的丰富来源,可调节肿瘤微环境中其他细胞(包括血管内皮细胞)的功能。本研究分析了他莫昔芬化疗对参与肿瘤外泌体血管生成的关键miRNA--miR-573表达的影响,并介绍了该miRNA与血管内皮生长因子(VEGF)信息传递途径相关的CD146基因之间的调控联系:购买 MCF-7 乳腺癌细胞并在完全培养基中培养。用他莫昔芬处理这些细胞,然后从培养基中提取它们的外泌体。分离外泌体的 RNA,并采用实时聚合酶链反应(PCR)方法检测外泌体中 miR-573、VEGF 和 CD146 基因的表达:结果:研究结果表明,他莫昔芬治疗可增加MCF-7癌细胞外泌体中miR-573的表达。结论:本实验结果表明,他莫昔芬治疗可增加 MCF-7 癌细胞外泌体中 miR-573 的表达,而药物治疗细胞外泌体中 CD146 和 VEGF 基因的表达呈下降趋势:本实验结果表明,用他莫昔芬处理乳腺癌细胞,可通过增加 miR-573 来减少血管内皮生长因子和 CD146 的表达。因此,血管生成减少,从而发挥其抗肿瘤作用。
{"title":"Investigating changes in the post-transcriptional pattern of VEGF and CD146 genes carrying miR-573 in breast cancer cells treated with tamoxifen.","authors":"M Abyar, M Kavousi, F Jamshidian","doi":"10.48095/ccko2023447","DOIUrl":"10.48095/ccko2023447","url":null,"abstract":"<p><strong>Background: </strong>Recent developments regarding the contribution of microRNAs (miRNAs) to tumor angiogenesis and the oncogenic effects of miRNAs point to their potential role in breast cancer angiogenesis. Tumor-derived exosomes are considered a rich source of miRNAs that can regulate the function of other cells in the tumor microenvironment, including vascular endothelial cells. This study analyzes the effect of tamoxifen chemotherapy on the expression of a key miRNA, miR-573, involved in the angiogenesis of the tumor exosomes and introduces a regulatory link between this miRNA and the CD146 gene associated with the vascular endothelial growth factor (VEGF) messaging pathway.</p><p><strong>Materials and methods: </strong>MCF-7 breast cancer cells were purchased and cultured in a complete culture medium. These cells were treated with tamoxifen and then their exosomes were extracted from the culture medium. The RNAs of the exosomes were isolated and the expression of miR-573, VEGF, and CD146 genes in the exosomes was investigated using the real-time polymerase chain reaction (PCR) method.</p><p><strong>Results: </strong>The results of this study showed that tamoxifen treatment increased the expression of miR-573 in exosomes derived from MCF-7 cancer cells. The expression of CD146 and VEGF genes in drug-treated cell exosomes had a downward pattern.</p><p><strong>Conclusion: </strong>The results of this experiment demonstrated that the treatment of breast cancer cells with tamoxifen reduces the expression of VEGF and CD146 by increasing miR-573. Thus, angiogenesis is reduced and, therefore, its anti-tumor effects are applied.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The endoplasmic reticulum and its signaling pathways - a novel target for multiple myeloma treatment. 内质网及其信号通路--治疗多发性骨髓瘤的新靶点。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.48095/ccko2023440
A Dostálová, M Vlachová, J Gregorová, L Moráň, L Pečinka, V Gabrielová, P Vaňhara, S Ševčíková

Background: The endoplasmic reticulum (ER), an organelle composed of a system of cisternae and tubules, is essential for many cellular processes, including protein synthesis and transport. When misfolded proteins accumulate in the ER lumen, ER stress is induced, and the subsequent response to the disruption of homeostasis is the activation of the unfolded protein response (UPR). The purpose of this process is to restore homeostasis by increasing the capacity of the ER and its ability to fold proteins. Activation of the homeostatic UPR occurs via one of three transmembrane proteins, inositol-requiring enzyme 1a (IRE1a), protein kinase R-like ER kinase (PERK) and activating transcription factor 6 (ATF6). Failure of the attempt to restore homeostasis, on the other hand, leads to the development of terminal UPR and apoptosis via hyperactivation of the same proteins. Activation of UPR has been described in many malignancies, including multiple myeloma (MM), which is characterized by malignant transformation of plasma cells and increased monoclonal immunoglobulin synthesis, where the role of the ER is of particular importance. Despite advances in the treatment of MM, the disease remains difficult to treat and targeting signaling pathways associated with the UPR could, for example, enhance the effect of proteasome inhibitors.

Purpose: This review intends to present the molecular response to ER stress under physiological circumstances and in the context of cancer, particularly with regard to potential therapeutic targets in MM.

背景:内质网(ER)是一个由液胞和小管系统组成的细胞器,对许多细胞过程(包括蛋白质合成和运输)至关重要。当折叠错误的蛋白质在ER腔内积累时,ER压力就会被诱发,随后对平衡被破坏的反应就是激活未折叠蛋白反应(UPR)。这一过程的目的是通过提高ER的容量及其折叠蛋白质的能力来恢复平衡。平衡性 UPR 是通过三种跨膜蛋白(肌醇需要酶 1a(IRE1a)、蛋白激酶 R 样 ER 激酶(PERK)和活化转录因子 6(ATF6))之一激活的。另一方面,如果恢复平衡的努力失败,就会通过过度激活相同的蛋白质,导致终末 UPR 的发展和细胞凋亡。包括多发性骨髓瘤(MM)在内的许多恶性肿瘤都出现了 UPR 激活现象,MM 的特点是浆细胞恶性转化和单克隆免疫球蛋白合成增加,其中 ER 的作用尤为重要。尽管在治疗 MM 方面取得了进展,但这种疾病仍然难以治疗,针对与 UPR 相关的信号通路可以增强蛋白酶体抑制剂的效果等。目的:本综述旨在介绍在生理情况下和癌症背景下对 ER 应激的分子反应,特别是有关 MM 的潜在治疗靶点。
{"title":"The endoplasmic reticulum and its signaling pathways - a novel target for multiple myeloma treatment.","authors":"A Dostálová, M Vlachová, J Gregorová, L Moráň, L Pečinka, V Gabrielová, P Vaňhara, S Ševčíková","doi":"10.48095/ccko2023440","DOIUrl":"10.48095/ccko2023440","url":null,"abstract":"<p><strong>Background: </strong>The endoplasmic reticulum (ER), an organelle composed of a system of cisternae and tubules, is essential for many cellular processes, including protein synthesis and transport. When misfolded proteins accumulate in the ER lumen, ER stress is induced, and the subsequent response to the disruption of homeostasis is the activation of the unfolded protein response (UPR). The purpose of this process is to restore homeostasis by increasing the capacity of the ER and its ability to fold proteins. Activation of the homeostatic UPR occurs via one of three transmembrane proteins, inositol-requiring enzyme 1a (IRE1a), protein kinase R-like ER kinase (PERK) and activating transcription factor 6 (ATF6). Failure of the attempt to restore homeostasis, on the other hand, leads to the development of terminal UPR and apoptosis via hyperactivation of the same proteins. Activation of UPR has been described in many malignancies, including multiple myeloma (MM), which is characterized by malignant transformation of plasma cells and increased monoclonal immunoglobulin synthesis, where the role of the ER is of particular importance. Despite advances in the treatment of MM, the disease remains difficult to treat and targeting signaling pathways associated with the UPR could, for example, enhance the effect of proteasome inhibitors.</p><p><strong>Purpose: </strong>This review intends to present the molecular response to ER stress under physiological circumstances and in the context of cancer, particularly with regard to potential therapeutic targets in MM.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ewing's sarcoma of the urinary bladder - the urologic and pathologic differential diagnosis and current therapeutic options. 膀胱尤文氏肉瘤--泌尿学和病理学鉴别诊断及当前治疗方案。
Q4 Medicine Pub Date : 2023-01-01
M Král, D Kurfúrstová, I Hartmann, H Študentová, J Škarda

Background: Bladder cancer is 11th most common cancer worldwide. Histologically, most of the tumors are classified as urothelial carcinomas. Less common variants (squamous cell or adenocarcinomas) usually comprise up to 10% of cases. Other types of tumors are exceptional. The finding of Ewing's sarcoma in the bladder is considered extremely rare.

Case: We present the case of a 54-year-old female patient examined for painless hematuria. During the follow-up examination, a bulky tumor of the bladder was detected, but considering the extent of the bladder tumor, only a diagnostic transurethral resection was possible. According to the primary staging, the disease was already advanced at the time of admission with metastatic spread, anemia and present obstruction of the upper urinary tract.

Results: Histologically, Ewing's sarcoma was surprisingly demonstrated in the urinary bladder. Anemia caused by hematuria and advanced disease was corrected by blood transfusions and obstruction of the right kidney by puncture nephrostomy. However, despite a very quick diagnosis, completion of staging and preparation of the patient for further treatment, the patient had died before the planned systemic treatment began.

Conclusion: The diagnosis of Ewing's sarcoma is identical to that of the other bladder tumors, i.e. transurethral resection. In the case of confirmation of this histological type, it is necessary to complete staging examinations and start multimodal treatment. Early systemic chemotherapy plays a key role and if metastatic spread is excluded, radical cystectomy or radiotherapy are included, too. The aim of our communication is to present a rare case of this disease, discuss the differential diagnosis and point out the principles and possibilities of its treatment.

背景:膀胱癌是全球第 11 位最常见的癌症:膀胱癌是全球第 11 位最常见的癌症。在组织学上,大多数肿瘤被归类为尿路上皮癌。较少见的变种(鳞状细胞癌或腺癌)通常占病例的 10%。其他类型的肿瘤则比较少见。在膀胱中发现尤文氏肉瘤的病例极为罕见:本病例是一名 54 岁的女性患者,因无痛性血尿接受检查。在随访检查中,发现膀胱内有一个巨大肿瘤,但考虑到膀胱肿瘤的范围,只能进行诊断性经尿道切除。根据初诊分期,患者入院时病情已属晚期,出现转移扩散、贫血和上尿路梗阻:组织学检查显示,膀胱中竟然有尤文氏肉瘤。血尿和晚期疾病导致的贫血通过输血得到了纠正,右肾梗阻通过穿刺肾造瘘术得到了治疗。然而,尽管诊断、分期和进一步治疗的准备工作很快就完成了,但患者还是在计划的系统治疗开始之前去世了:结论:尤文肉瘤的诊断与其他膀胱肿瘤的诊断相同,即经尿道切除。如果确诊为这种组织学类型,就必须完成分期检查并开始多模式治疗。早期全身化疗起着关键作用,如果排除了转移扩散的可能性,还可以进行根治性膀胱切除术或放疗。我们的文章旨在介绍这种疾病的一个罕见病例,讨论鉴别诊断,并指出治疗原则和可能性。
{"title":"Ewing's sarcoma of the urinary bladder - the urologic and pathologic differential diagnosis and current therapeutic options.","authors":"M Král, D Kurfúrstová, I Hartmann, H Študentová, J Škarda","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is 11th most common cancer worldwide. Histologically, most of the tumors are classified as urothelial carcinomas. Less common variants (squamous cell or adenocarcinomas) usually comprise up to 10% of cases. Other types of tumors are exceptional. The finding of Ewing's sarcoma in the bladder is considered extremely rare.</p><p><strong>Case: </strong>We present the case of a 54-year-old female patient examined for painless hematuria. During the follow-up examination, a bulky tumor of the bladder was detected, but considering the extent of the bladder tumor, only a diagnostic transurethral resection was possible. According to the primary staging, the disease was already advanced at the time of admission with metastatic spread, anemia and present obstruction of the upper urinary tract.</p><p><strong>Results: </strong>Histologically, Ewing's sarcoma was surprisingly demonstrated in the urinary bladder. Anemia caused by hematuria and advanced disease was corrected by blood transfusions and obstruction of the right kidney by puncture nephrostomy. However, despite a very quick diagnosis, completion of staging and preparation of the patient for further treatment, the patient had died before the planned systemic treatment began.</p><p><strong>Conclusion: </strong>The diagnosis of Ewing's sarcoma is identical to that of the other bladder tumors, i.e. transurethral resection. In the case of confirmation of this histological type, it is necessary to complete staging examinations and start multimodal treatment. Early systemic chemotherapy plays a key role and if metastatic spread is excluded, radical cystectomy or radiotherapy are included, too. The aim of our communication is to present a rare case of this disease, discuss the differential diagnosis and point out the principles and possibilities of its treatment.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Klinicka Onkologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1